Skip to main content

MEJORA Y EVALUACION DE VACUNAS BASADAS EN VECTORES VIRICOS Y MICROPARTICULAS FRENTE A ORBIVIRUS Y BUNYAVIRUS TRANSMITIDOS POR ARTROPODOS: HACIA EL DESARROLLO DE VACUNAS MULTIV

AGL2014-57430-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre INSTITUTO NACIONAL DE INVESTIGACIÓN Y TECNOLOGÍA AGRARIA Y ALIMENTARIA - CSIC

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Pathological Characterization Of IFNAR(-/-) Mice Infected With Bluetongue Virus Serotype 4

  • Marín López, Alejandro
  • Bermúdez Pose, Roberto
  • Calvo Pinilla, Eva
  • Moreno, Sandra
  • Brun, Alejandro
  • Ortego, Javier
Bluetongue virus (BTV) replicates in lymphoid tissues where infected mononuclear leukocytes secrete proinflammatory and vasoactive mediators that can contribute to bluetongue (BT) pathogenesis. Using the well-characterized IFNAR(-/-) mice animal model, we have now studied the histopathology and dynamics of leukocyte populations in different target tissues (spleen, thymus, and lung) during BTV-4 infection by histological and immunohistochemical techniques. The spleen and thymus of BTV-4 infected mice showed severe lymphoid depletion on H&E stained sections. This finding was confirmed by IHC, showing moderate decreased immunopositivity against CD3 in the thymus, and scarce immunoreactivity against CD3 and CD79 in the rest of the white pulp in the spleen, together with an increase in MAC387 immunostaining. BTV-4 infection also induced the expression of active caspase-3 in the spleen, where apoptotic debris was observed by H&E. A dramatic increase in iNOS immunoreactivity associated to necrotic areas of the white pulp was observed, being less noticeable in the thymus and the lung. The induction of pro-inflammatory cytokines in tissues where BTV replicates was evaluated by measuring transcript levels by RT-qPCR. BTV-4 infection led to enhance transcription of IFN-γ, TNF, IL-6, IL-12-p40, and IL-1β mRNA in the thymus, spleen and lung, correlating with the level of virus replication in these tissues. Disease progression and pathogenesis in IFNAR(-/-) mice closely mimics hallmarks of bluetongue disease in ruminants. IFNAR(-/-) mice are a good choice to facilitate a faster advance in the field of orbiviruses.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(−/−) mice conferring protection against serotypes 1 and 4 of bluetongue virus

  • Marín López, Alejandro
  • Calvo Pinilla, Eva
  • Barriales, Diego
  • Lorenzo, Gema
  • Benavente Martínez, Francisco Javier
  • Brun, Alejandro
  • Martínez Costas, José Manuel
  • Ortego, Javier
Bluetongue virus (BTV) is the causative agent of bluetongue disease (BT), which affects domestic and wild ruminants. At the present, 27 different serotypes have been documented. Vaccination has been demonstrated as one of the most effective methods to avoid viral dissemination. To overcome the drawbacks associated with the use of inactivated and attenuated vaccines we engineered a new recombinant BTV vaccine candidate based on proteins VP2, VP7, and NS1 of BTV-4 that were incorporated into avian reovirus muNS-Mi microspheres (MS-VP2/VP7/NS1) and recombinant modified vaccinia virus Ankara (rMVA). The combination of these two antigen delivery systems in a heterologous prime-boost vaccination strategy generated significant levels of neutralizing antibodies in IFNAR(−/−) mice. Furthermore, this immunization strategy increased the ratio of IgG2a/IgG1 in sera, indicating an induction of a Th1 response, and elicited a CD8 T cell response. Immunized mice were protected against lethal challenges with the homologous serotype 4 and the heterologous serotype 1 of BTV. All these results support the strategy based on microspheres in combination with rMVAs as a promising multiserotype vaccine candidate against BTV
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A protective bivalent vaccine against Rift Valley fever and bluetongue

  • Calvo Pinilla, Eva María
  • Marín-López, A.
  • Moreno, Sandra
  • Lorenzo, Gema
  • Utrilla-Trigo, S.
  • Jiménez-Cabello, L.
  • Benavides, Julio
  • Nogales, Aitor
  • Blasco, Rafael
  • Brun Torres, Alejandro
  • Ortego, Javier
12 páginas, 9 figuras., Rift Valley fever (RVF) and bluetongue (BT) are two important ruminant diseases transmitted by arthropods. Both viruses have shown important geographic spread leading to endemicity of BT virus (BTV) in Africa and Europe. In this work, we report a dual vaccine that simultaneously induces protective immune responses against BTV and RVFV based on modified vaccinia Ankara virus (MVA) expressing BTV proteins VP2, NS1, or a truncated form of NS1 (NS1-Nt), and RVFV Gn and Gc glycoproteins. IFNAR mice immunized with two doses of MVA-GnGc-VP2 developed a significant neutralizing antibody response against BTV-4 and RVFV. Furthermore, the homologous prime-boost immunization with MVA-GnGc-NS1 or MVA-GnGc-NS1-Nt triggered neutralizing antibodies against RVFV and NS1-specific cytotoxic CD8+ T cells in mice. Moreover, all mice immunized with MVA-GnGc-NS1 or MVA-GnGc-NS1-Nt remained healthy after lethal challenge with RVFV or BTV-4. The homologous prime-boost vaccination with MVA-GnGc-NS1, which was the best immunization strategy observed in mice, was assayed in sheep. Clinical signs and viremia were absent or highly reduced in vaccinated sheep after challenge with BTV-4 or RVFV. These results indicate that MVA-GnGc-NS1 vaccination elicits immune protection against RVFV and BTV in sheep., This work was supported by grants AGL-2014-57430R, AGL2017-83226R, and AGL2017-82570-R from the Spanish Ministry of Science and EU Horizon 2020 Program (European Comission Grant Agreement No. 727393-PALE-Blu). SUT was a recipient of a predoctoral fellowship from the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Centro de Investigación en Sanidad Animal (program FPI-SGIT-2018)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge

  • Moreno, Sandra
  • Calvo Pinilla, Eva María
  • Devignot, S.
  • Weber, Friedemann
  • Ortego, Javier
  • Brun Torres, Alejandro
25 Pág., Many ruminant diseases of viral aetiology can be effectively prevented using appropriate vaccination measures. For diseases such as Rift Valley fever (RVF) the long inter-epizootic periods make routine vaccination programs unfeasible. Coupling RVF prophylaxis with seasonal vaccination programmes by means of multivalent vaccine platforms would help to reduce the risk of new RVF outbreaks., AB is supported by grants AGL2014-57430R and AGL2017-83226R from the Spanish Ministry of Science, and grant S2018/BAA 4370 from Comunidad de Madrid R&D in Technologies Program. JO is supported by grants AGL2014-57430R and AGL2017-82570R from the Spanish Ministry of Science and Innovation and European Union’s Horizon 2020 research and innovation program under grant proposal 727393-2. SMF is a recipient of a pre-doctoral fellowship program from the Spanish Ministry of Science and innovation. FW is supported by the CCHF Vaccine consortium that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 732732, and by the Swedish Research Council(Vetenskapsrådet, VR) section Research Environment, Infection Biology (contract number 2018-05766). The funding sources had no involvement in the study design nor in the writing of the report and the decision to submit the article for publication, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Inhibition of Orbivirus Replication by Aurintricarboxylic Acid

  • Alonso, Celia
  • Utrilla-Trigo, S.
  • Calvo Pinilla, Eva María
  • Jiménez-Cabello, L.
  • Ortego, Javier
  • Nogales, Aitor
14 Pág., Bluetongue virus (BTV) and African horse sickness virus (AHSV) are vector-borne viruses belonging to the Orbivirus genus, which are transmitted between hosts primarily by biting midges of the genus Culicoides. With recent BTV and AHSV outbreaks causing epidemics and important economy losses, there is a pressing need for efficacious drugs to treat and control the spread of these infections. The polyanionic aromatic compound aurintricarboxylic acid (ATA) has been shown to have a broad-spectrum antiviral activity. Here, we evaluated ATA as a potential antiviral compound against Orbivirus infections in both mammalian and insect cells. Notably, ATA was able to prevent the replication of BTV and AHSV in both cell types in a time- and concentration-dependent manner. In addition, we evaluated the effect of ATA in vivo using a mouse model of infection. ATA did not protect mice against a lethal challenge with BTV or AHSV, most probably due to the in vivo effect of ATA on immune system regulation. Overall, these results demonstrate that ATA has inhibitory activity against Orbivirus replication in vitro, but further in vivo analysis will be required before considering it as a potential therapy for future clinical evaluation., This work was supported by the EU Horizon 2020 Program (European Commission grant agreement no. 727393-PALE-Blu [to J.O.]) and the Spanish Ministry of Economy and Competitiveness (MINECO) grant AGL2014-57430-R (to J.O. and A.N.). A.N. is supported by a MINECO “Ramon y Cajal” Incorporación grant (RYC-2017). S.U-T. is supported by an INIA SGIT-FPI predoctoral fellowship., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara

  • Marín-López, A.
  • Barreiro-Piñeiro, Natalia
  • Utrilla-Trigo, S.
  • Barriales, Diego
  • Benavente, Javier
  • Nogales, Aitor
  • Martínez-Costas, José Manuel
  • Ortego, Javier
  • Calvo Pinilla, Eva María
8 Pág., African horse sickness virus (AHSV) is an insect-borne pathogen that causes acute disease in horses and other equids. In an effort to improve the safety of currently available vaccines and to acquire new knowledge about the determinants of AHSV immunogenicity, new generation vaccines are being developed. In this work we have generated and tested a novel immunization approach comprised of nonstructural protein 1 (NS1) of AHSV serotype 4 (AHSV-4) incorporated into avian reovirus muNS protein microspheres (MS-NS1) and/or expressed using recombinant modified vaccinia virus Ankara vector (MVA-NS1). The protection conferred against AHSV by a homologous MS-NS1 or heterologous MS-NS1 and MVA-NS1 prime/boost was evaluated in IFNAR (-/-) mice. Our results indicate that immunization based on MS-NS1 and MVA-NS1 afforded complete protection against the infection with homologous AHSV-4. Moreover, priming with MS-NS1 and boost vaccination with MVA-NS1 (MS-MVA-NS1) triggered NS1 specific cytotoxic CD8 + T cells and prevented AHSV disease in IFNAR (-/-) mice after challenge with heterologous serotype AHSV-9. Cross-protective immune responses are highly important since AHS can be caused by nine different serotypes, which means that a universal polyvalent vaccination would need to induce protective immunity against all serotypes., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades, Spain (AGL-2014-57430-R, AGL2017-82570-R and BFU2013-43513-R). The Xunta de Galicia [Centro singular de investigación de Galicia accreditation 2016-2019 (ED431G/09) and ED431B 2018/04], and the European Regional Development Fund (ERDF) are gratefully acknowledged. We thank Rebeca Menaya for excellent technical assistance., Peer reviewed